NEW YORK (GenomeWeb News) – Pathwork Diagnostics today announced a deal to offer its Pathwork Tissue of Origin Test for cancer diagnosis in China.

The deal with Kindstar Global, which claims to be the largest esoteric diagnostic testing business in China, expands the Redwood City, Calif.-based company's international network of test and service providers, Pathwork said. The agreement is the first international in vitro diagnostic deal for the company, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.